12:00 AM
 | 
Apr 12, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VGX-3100: Completed Phase I enrollment

Inovio completed enrollment of 18 females with a history of cervical intraepithelial neoplasia (CIN) 2/3 in an open-label, dose-escalation, U.S. Phase I trial...

Read the full 95 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >